Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 13/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | BACE1 | P56817 | 4/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25273586 | 0.94 | MEN1 (0.46) | MEN1KMT2AACHEBACE1AURKA | |
| SCHEMBL31501671 | 0.93 | MEN1 (0.49) | MEN1KMT2AACHEBACE1AURKA | |
| SCHEMBL30456045 | 0.88 | MEN1 (0.46) | MEN1KMT2AACHEBACE1AURKA | |
| SCHEMBL25271281 | 0.88 | MEN1 (0.46) | MEN1KMT2AACHEBACE1AURKA | |
| SCHEMBL31501615 | 0.87 | MEN1 (0.41) | MEN1KMT2AAURKA | |
| SCHEMBL31501655 | 0.87 | MEN1 (0.49) | MEN1KMT2AACHEBACE1AURKA | |
| SCHEMBL31501609 | 0.85 | MEN1 (0.41) | MEN1KMT2AACHEBACE1BRAF | |
| SCHEMBL31501640 | 0.84 | MEN1 (0.53) | MEN1KMT2AACHEBACE1EGFR | |
| SCHEMBL31501603 | 0.82 | MEN1 (0.41) | MEN1KMT2AAURKA | |
| SCHEMBL31501678 | 0.82 | MEN1 (0.51) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | claimed |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4444313-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | MLLT1, MEN1, BMI1 | MEN1 2/4885KMT2A 8/4885ACHE 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.